Clinical Trials

Genkyotex’s liver disease drug GKT831 succeeds in phase 2 trial

Genkyotex’s NOX1/4 inhibitor GKT831 has succeeded in a phase 2 trial in primary biliary cholangitis (PBC), a type of liver disease, by meeting both primary and secondary interim efficacy endpoints.

BMS, Infinity to assess Opdivo-IPI-549 combo in urothelial cancer

A clinical trial collaboration has been formed to assess Bristol-Myers Squibb's (BMS) Opdivo in combination with Infinity Pharmaceuticals' IPI-549 in patients with advanced urothelial cancer.

Verona enrolls last patient in phase 2 trial for RPL554 in COPD

Verona Pharma has completed patient enrollment for a phase 2 trial for its nebulized RPL554 as an add-on to dual therapy using long-acting anti-muscarinic / long-acting beta2-agonists (LAMA/LABA) and triple therapy (LAMA/LABA with an inhaled corticosteroid) in the maintenance treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD).

ViiV Healthcare’s HIV-1 drug fostemsavir succeeds in phase 3 trial

ViiV Healthcare has reported positive results for its phase 3 BRIGHTE study of investigational fostemsavir at 48 weeks in heavily treatment-experienced (HTE) patients with HIV-1 infection.

Pfizer, Novartis partner to advance treatment of NASH

Pfizer has signed a non-exclusive clinical development agreement with Novartis to study one or more combination therapies for the treatment of non-alcoholic steatohepatitis (NASH).

Novartis’ brolucizumab meets primary endpoint in phase III nAMD trial

Swiss drugmaker Novartis released additional phase III results of brolucizumab from year two, which reaffirm superiority of the drug over aflibercept in reducing retinal fluid in patients with neovascular age-related macular degeneration (nAMD).

Esperion’s cholesterol drug bempedoic acid succeeds in phase 3 trial

Esperion’s cholesterol drug bempedoic acid has succeeded in a phase 3 trial by achieving its efficacy endpoints and other key measures in patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH).

First subject dosed in phase 1 trial of BMS-986179 with Enhanze technology

Bristol-Myers Squibb (BMS) has dosed the first subject in a clinical trial assessing the safety, pharmacokinetics and pharmacodynamics of BMS-986179, an investigational anti-CD-73 antibody, using Halozyme Therapeutics' Enhanze drug delivery technology.

Daiichi Sankyo signs clinical trial collaboration deal with Merck and Pfizer

Daiichi Sankyo has entered into a clinical trial collaboration agreement with Merck and Pfizer to evaluate the combination of its [fam-] trastuzumab deruxtecan (DS-8201) with avelumab and/or an investigational damage response (DDR) inhibitor of Merck, in patients with HER2 expressing or mutated solid tumors.